| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4237915
Max Phase: Preclinical
Molecular Formula: C15H16N4O
Molecular Weight: 268.32
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: Cc1coc2ncnc(Nc3ccc(N(C)C)cc3)c12
Standard InChI: InChI=1S/C15H16N4O/c1-10-8-20-15-13(10)14(16-9-17-15)18-11-4-6-12(7-5-11)19(2)3/h4-9H,1-3H3,(H,16,17,18)
Standard InChI Key: AGTISXVWCFCHFO-UHFFFAOYSA-N
Associated Targets(Human)
A-431 (6446 Activities)
PDGFRB Tclin Platelet-derived growth factor receptor beta (5195 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
KDR Tclin Vascular endothelial growth factor receptor 2 (20924 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
A10 (235 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Chorioallantoic membrane (375 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 268.32 | Molecular Weight (Monoisotopic): 268.1324 | AlogP: 3.34 | #Rotatable Bonds: 3 |
| Polar Surface Area: 54.19 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 6.00 | CX LogP: 3.23 | CX LogD: 3.22 |
| Aromatic Rings: 3 | Heavy Atoms: 20 | QED Weighted: 0.79 | Np Likeness Score: -0.95 |
References
| 1. Devambatla RKV, Choudhary S, Ihnat M, Hamel E, Mooberry SL, Gangjee A.. (2018) Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential., 28 (18): [PMID:30098869] [10.1016/j.bmcl.2018.07.039] |
Source
Source(1):